1. FDA news release. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. Current as of 11//22/2022. Retrieved December 7, 2022.
2. Naddaf M. Researchers welcome $3.5 million haemophilia gene therapy – but questions remain. Nature. https://www.nature.com/articles/d41586-022-04327-7. Posted December 6, 2022. Retrieved December 7, 2022.
3. CSL Behring. Final analysis of pivotal HOPE-B study demonstrates durable and sustained therapeutic effect of etranacogene dezaparvovec gene therapy in hemophilia b – data presented at EAHAD 2022 [media release]. February 4, 2022. https://www.cslbehring.com/.
4. CSL Behring. CSL's novel gene therapy HEMGENIX® (etranacogene dezaparvovec-drlb) demonstrates durable protection and sustained factor IX activity levels for people living with hemophilia B at 24-months post-treatment [media release]. December 10, 2022. https://www.cslbehring.com/.